TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03086226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosravuconazole
Description: Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosravuconazole
Description: Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
Study: NCT03995355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 9618X investigational lipid eye drops
Description: Test Eye Drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blink® Tears
Description: Control Eye Drops
Study: NCT01257607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIM-D3 Ophthalmic Solution
Description: 28 Days, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIM-D3 Ophthalmic Solution
Description: 28 Days, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: 28 Days, BID
Study: NCT03474783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
Study: NCT00494507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (double-blind)
Description: 50mg tablet; maximum dosage 400mg/day
Study: NCT03632915

Intervention type: DRUG
Intervention: Phenobarbital
Description: Standard of care

Intervention type: DRUG
Intervention: Ketamine
Description: Standard of care
Study: NCT00494507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (double-blind)
Description: 50mg tablet; maximum dosage 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (double-blind)
Description: Inactive substance manufactured to look like Dichlorphenamide 50mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (double-blind)
Description: Inactive substance manufactured to look like Dichlorphenamide 50mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day
Study: NCT04545710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg daily
Study: NCT01433094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falloon et al. Psychoeducation Program
Description: The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Treatment
Description: The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
Study: NCT03632915

Intervention type: DRUG
Intervention: Valproic Acid
Description: Standard of care
Study: NCT03086226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: This will be the active comparator
Study: NCT00945932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study: NCT04298632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Education Program
Description: this is a pesticide safety education program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Education Program
Description: this is a pesticide safety education program
Study: NCT02358512

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Bolus feeds or continuous feeds during a 10-day ICU stay

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Description: Bolus feeds or continuous feeds during a 10-day ICU stay
Study: NCT02412917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: antiviral nucleoside analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: antiviral nucleoside analog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: antiviral nucleoside analog
Study: NCT05506293

Intervention type: PROCEDURE
Intervention: percutaneous paravalvular leak closure
Description: the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~* Amplatzer vascular plug 3~* occlutech paravalvular leak device~* amplatzer vascular plug 2~* amplatzer muscular ventricular septal defect~* amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design.
Study: NCT00980031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 25mg PO daily (QD)for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Tablet
Description: Lactose tablet
Study: NCT04110730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Upper-limb Prosthesis
Description: The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Intervention
Description: An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Intervention
Description: An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
Study: NCT02074280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
Study: NCT01668914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IM-SLNB
Description: IM-SLNB is performed according to the pre-operative lymphoscintigraphy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-SC
Description: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histologic Examination
Description: All IMSLNs were analyzed by histologic examination for future therapy planning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSG
Description: lymphoscintigraphy was performed 0.5\~1.0 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
Study: NCT03146104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
Study: NCT01159665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection
Study: NCT00348686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 16 mg once daily in oral tablet form
Study: NCT03146104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
Study: NCT06583057

Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
Study: NCT03098745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somofilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A - Proclear (PC)
Description: contact lens
Study: NCT03178669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobitolimod
Description: Rectal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobitolimod
Description: Rectal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobitolimod
Description: Rectal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobitolimod
Description: Rectal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution manufactured to mimic cobitolimod
Study: NCT03876665

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02953886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
Study: NCT00520260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromfenac
Description: 0.09%, BID, 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: 0.4%, BID, 6 weeks
Study: NCT00908102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate
Description: A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate
Description: A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate
Description: A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild
Description: A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild
Description: A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
Study: NCT00348686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 32 mg once daily in oral tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: 5 mg once daily in oral tablet form
Study: NCT00908102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
Study: NCT04022707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed circuit resistance training
Description: The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed circuit resistance training
Description: The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational control
Description: Lectures on health and fitness
Study: NCT00908102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
Study: NCT04022707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational control
Description: Lectures on health and fitness
Study: NCT01061658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine
Description: Higher dosage of vaccine
Study: NCT00908102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
Study: NCT00084487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV
Study: NCT01978444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 lymphadenectomy plus CME

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 lymphadenectomy
Study: NCT05339230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum and SPC-flakes active or placebo
Description: Foods for specific medical purposes or corresponding placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Salovum and SPC-flakes active or placebo
Description: Foods for specific medical purposes or corresponding placebo
Study: NCT01573156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light activated WST11
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
Study: NCT02387489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief in-person motivational intervention
Description: Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Brief Intervention
Description: Computer-delivered motivational intervention tailored to participants' risk behaviors.
Study: NCT00225784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab/Gemcitabine
Description: Once weekly Cetuximab, twice weekly Gemcitabine for six weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Daily radiotherapy for 28 days
Study: NCT01009086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: SC injections
Study: NCT00348686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: 10 mg once daily in oral tablet form
Study: NCT02114723

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Medical Taping Concept
Description: The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Taping Concept
Description: The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears
Study: NCT03920046

Intervention type: BEHAVIORAL
Intervention: Control Group
Description: The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.